A prospective, multicentre phase II study comparing the efficacy and safety of second or third-line masitinib + irinotecan vs masitinib + gemcitabine in patients with recurrent/relapsed +/or metastatic head and neck squamous cell carcinoma

Trial Profile

A prospective, multicentre phase II study comparing the efficacy and safety of second or third-line masitinib + irinotecan vs masitinib + gemcitabine in patients with recurrent/relapsed +/or metastatic head and neck squamous cell carcinoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Jul 2015

At a glance

  • Drugs Masitinib (Primary) ; Gemcitabine; Irinotecan
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Jul 2015 In July 2015, an interim analysis was conducted by the DSMB; it was recommended that the study continue as planned, according to an AB Science media release.
    • 04 Sep 2013 New trial record
    • 30 Aug 2013 The first patient has been recruited, according to an AB Science media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top